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with higher risk, but low participation rates, active case-
detection of CT-infections in “high-prevalence-area’s”
needs a concerted approach of different providers and
community organisations, both in secondary as in pri-
mary prevention. The pharmacist can contribute if proper
liaison is made with primary care providers and/or public
health services for (partner-)treatment, counseling, and
comprehensive sexual health care.
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OBJECTIVE: The UK is a low endemic area for hepati-
tis B virus. Nevertheless, the National Health Service
(NHS) burden of managing the disease and its long term
sequelae is thought to be great. Understanding the extent
of this cost is needed to estimate the budget impact of
adopting therapies that avoid morbidity and mortality.
The purpose of this study is to estimate the resources and
costs associated with major health states of chronic
hepatitis B (CHB). METHODS: Annual health care
resource use was estimated by a panel of expert hepatol-
ogists for patients with chronic active hepatitis B (CAHB),
compensated and decompensated cirrhosis (including
ascites, bacterial peritonitis, variceal haemorrhage and
hepatic encephalopathy), and hepatocellular carcinoma.
Liver transplantation costs were obtained from published
sources and unit costs from NHS-relevant sources.
RESULTS: In the UK 39% of CHB patients receive antivi-
ral therapy. The estimated annual cost is £2503 for
CAHB and £2631 for compensated cirrhosis managed
with antivirals. For patients without antivirals (61%),
annual costs are £547 (CAHB) and £745 (compensated
cirrhosis). Estimated annual cost for decompensated cir-
rhosis is £5842 using a distribution across the possible
manifestations of the disease. Hepatocellular carcinoma
is £6167 annually with less than 25% of patients receiv-
ing chemotherapy. Liver transplantation costs over
£31,000 for the transplantation and £10,700 in the ﬁrst
year post transplant. CONCLUSIONS: The direct
medical costs of CHB are substantial. Slowing or stop-
ping disease progression could reduce the morbidity and
mortality burden on patients and the cost burden for the
NHS.
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OBJECTIVES: To illustrate how value of information
analyses can be used to inform the efﬁcient design of
future research using an updated cost-effectiveness model
of Zanamivir, Oseltamivir and Amantadine versus normal
treatment for persons with inﬂuenza-like-illness (ILI).
METHODS: Systematic review and meta-analysis of evi-
dence relating to the effectiveness in terms of length of
illness, complication rate and adverse event proﬁle for all
three antiviral treatments was used to inform a proba-
bilistic decision model. The incremental cost per QALY
was estimated and Monte Carlo simulation used to 
generate a cost-effectiveness acceptability curve. The
expected value of perfect information (EVPI) was calcu-
lated. Partial EVPI for each of the uncertain parameters
in the model was calculated using a two-level simulation
approach. This same approach was used to calculate the
expected value of sample information (EVSI) for a
number of different research designs. RESULTS: For
healthy adults the incremental cost per QALY of Aman-
tadine compared to no treatment is approximately £13k.
The ICER for Oseltamivir compared to Amantadine is
approximately £42k. Oseltamivir dominates Zanamivir.
However, these estimates are extremely uncertain, as
reﬂected in the cost effectiveness acceptability curve.
Value of information analyses indicate ﬁrstly, the value of
that uncertainty within the model and secondly, the most
efﬁcient design for future research aimed at reducing that
uncertainty. CONCLUSIONS: This paper illustrates the
application of recent advances in value of information
methods to the policy relevant issue of inﬂuenza treat-
ments. It indicates that improved knowledge of the pro-
portion of individuals that actually have inﬂuenza and the
QALY values associated with inﬂuenza are two variables
of particular value for future research.
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OBJECTIVES: Although pertussis is thought of most
often as a disease of childhood, it can occur in all ages.
It has been reported that pertussis in adolescents and
adults is on the rise in some Western countries. The goal
of this analysis was to determine the age distribution of
pertussis cases in hospitals in Germany, as well the length
of stay (LOS) and related costs per stay. METHODS:
Hospital discharge data by age group for pertussis cases
(ICD-9 codes: 033.0–033.9) admitted in 1999, and 2002
per diem hospital costs were obtained from the Federal
Statistical Bureau in Germany. These data were used to
develop LOS and inpatient hospital costs by age group
for a pertussis-related hospitalization. Cost estimates are
reported in €2002. RESULTS: Of the 1118 pertussis cases
identiﬁed, 52% were female. Ages ranged from infant to
75+ years. Those <1 year comprised 65% of admissions;
9% were between 1–5 years; 19% were between 6–15
years; 2% were aged 16–25 and 5% were 26 years and
